PULSAR (N=1,009) is a double-masked, active-controlled pivotal trial evaluating non-inferiority of EYLEA HD 12-week (n=335) and 16-week (n=338) dosing regimens compared to an 8-week dosing regimen ...

In Buenos Aires, Pulsar TV has become an on-the-road user of a Lawo digital audio console. The production company selected the mc²56 for its new HD/3-D OB vehicle. The first HD, 3G and 3-D broadcast ...

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Michael Stewart, MD, speaks about aflibercept 8 mg, the newly approved version of Eylea.

Iroquois, ON, Canada – November 26, 2008 – Argentina based Pulsar TV has invested in two Ross Vision QMD/X Multi-Definition Production Switchers in preparation for their HD conversion in 2010. Pulsar ...

BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer injections and longer dosing intervals in patients treated with aflibercept 8 mg ...

Pulsar PCMK 2 HE – Design and Features. The PCMK 2 HE rocks a simple design, and it’s a clean and attractive aesthetic with the black and white color scheme that contrasts really well.

“EYLEA HD was approved in the U.S. based in part on strong one-year efficacy and safety outcomes from PULSAR in wet age-related macular degeneration,” said Charles C. Wykoff, M.D., Ph.D ...

The PULSAR trial met its primary endpoint, with EYLEA HD patients achieving clinically equivalent vision gains to EYLEA at 48 weeks. As previously announced, EYLEA HD demonstrated durable vision ...

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years. TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron ...

TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal ...